Taking Stock of Retinal Gene Therapy: Looking Back and Moving Forward

Molecular Therapy

Volumn 25, Issue 5, 2017, Pages 1076-1094

  Bennett, Jean ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

clinical trials; gene therapy; retina

Indexed keywords

ADENO ASSOCIATED VIRUS VECTOR; VORETIGENE NEPARVOVEC; EYE PROTEIN;

ABCA4 GENE; AGE RELATED MACULAR DEGENERATION; CHM GENE; CHOROIDEREMIA; CHR2 GENE; CNGB3 GENE; COLOR BLINDNESS; DRUG APPROVAL; EXPERIMENTAL ANIMAL; GENE; GENE TARGETING; GENE THERAPY; GENOTYPE; HUMAN; LEBER CONGENITAL AMAUROSIS; LHON GENE; MERTK GENE; MOLECULARLY TARGETED THERAPY; MYO7A GENE; ND4 GENE; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHENOTYPE; RETINA DISEASE; RETINITIS PIGMENTOSA; RETINOSCHISIS; REVIEW; RPE65 GENE; RS1 GENE; S FLT GENE; STARGARDT DISEASE; USHER SYNDROME; VISUAL SYSTEM; ADMINISTRATION AND DOSAGE; ANIMAL; CHEMISTRY; CLINICAL TRIAL (TOPIC); DISEASE MODEL; GENE EXPRESSION; GENE VECTOR; GENETICS; HUMAN ADENOVIRUS C; INTRAOCULAR DRUG ADMINISTRATION; METABOLISM; MUTATION; PATHOLOGY; PROCEDURES; RETINA; TRENDS;

ADENOVIRUSES, HUMAN; ANIMALS; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; DRUG APPROVAL; EYE PROTEINS; GENE EXPRESSION; GENETIC THERAPY; GENETIC VECTORS; HUMANS; INJECTIONS, INTRAOCULAR; MUTATION; RETINA; RETINAL DISEASES;

EID: 85017180555     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1016/j.ymthe.2017.03.008     Document Type: Review

References (136)

1. 1 Bennett, J., Immune response following intraocular delivery of recombinant viral vectors. Gene Ther. 10 (2003), 977–982.
2. 2 Bowes, C., Li, T., Danciger, M., Baxter, L.C., Applebury, M.L., Farber, D.B., Retinal degeneration in the rd mouse is caused by a defect in the beta subunit of rod cGMP-phosphodiesterase. Nature 347 (1990), 677–680.
3. 3 Pittler, S.J., Baehr, W., Identification of a nonsense mutation in the rod photoreceptor cGMP phosphodiesterase beta-subunit gene of the rd mouse. Proc. Natl. Acad. Sci. USA 88 (1991), 8322–8326.
4. 4 Pittler, S.J., Keeler, C.E., Sidman, R.L., Baehr, W., PCR analysis of DNA from 70-year-old sections of rodless retina demonstrates identity with the mouse rd defect. Proc. Natl. Acad. Sci. USA 90 (1993), 9616–9619.
5. 5 Suber, M.L., Pittler, S.J., Qin, N., Wright, G.C., Holcombe, V., Lee, R.H., Craft, C.M., Lolley, R.N., Baehr, W., Hurwitz, R.L., Irish setter dogs affected with rod/cone dysplasia contain a nonsense mutation in the rod cGMP phosphodiesterase beta-subunit gene. Proc. Natl. Acad. Sci. USA 90 (1993), 3968–3972.
6. 6 Bennett, J., Tanabe, T., Sun, D., Zeng, Y., Kjeldbye, H., Gouras, P., Maguire, A.M., Photoreceptor cell rescue in retinal degeneration (rd) mice by in vivo gene therapy. Nat. Med. 2 (1996), 649–654.
7. 7 Maguire, A.M., Bennett, J., Nickle, A., Aguirre, G., Acland, G., Adenovirus-mediated gene transfer to canine retinal photoreceptors: effects of inflammation. Invest. Ophthalmol. Vis. Sci., 36, 1995, S777.
8. 8 Flannery, J.G., Zolotukhin, S., Vaquero, M.I., LaVail, M.M., Muzyczka, N., Hauswirth, W.W., Efficient photoreceptor-targeted gene expression in vivo by recombinant adeno-associated virus. Proc. Natl. Acad. Sci. USA 94 (1997), 6916–6921.
9. 9 Bennett, J., Duan, D., Engelhardt, J.F., Maguire, A.M., Real-time, noninvasive in vivo assessment of adeno-associated virus-mediated retinal transduction. Invest. Ophthalmol. Vis. Sci. 38 (1997), 2857–2863.
10. 10 Jomary, C., Vincent, K.A., Grist, J., Neal, M.J., Jones, S.E., Rescue of photoreceptor function by AAV-mediated gene transfer in a mouse model of inherited retinal degeneration. Gene Ther. 4 (1997), 683–690.
11. 11 Naldini, L., Blömer, U., Gage, F.H., Trono, D., Verma, I.M., Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. Proc. Natl. Acad. Sci. USA 93 (1996), 11382–11388.
12. 12 Farjo, R., Skaggs, J., Quiambao, A.B., Cooper, M.J., Naash, M.I., Efficient non-viral ocular gene transfer with compacted DNA nanoparticles. PLoS One, 1, 2006, e38.
13. 13 Cai, X., Conley, S.M., Nash, Z., Fliesler, S.J., Cooper, M.J., Naash, M.I., Gene delivery to mitotic and postmitotic photoreceptors via compacted DNA nanoparticles results in improved phenotype in a mouse model of retinitis pigmentosa. FASEB J. 24 (2010), 1178–1191.
14. 14 Han, Z., Banworth, M.J., Makkia, R., Conley, S.M., Al-Ubaidi, M.R., Cooper, M.J., Naash, M.I., Genomic DNA nanoparticles rescue rhodopsin-associated retinitis pigmentosa phenotype. FASEB J. 29 (2015), 2535–2544.
15. 15 Cai, X., Nash, Z., Conley, S.M., Fliesler, S.J., Cooper, M.J., Naash, M.I., A partial structural and functional rescue of a retinitis pigmentosa model with compacted DNA nanoparticles. PLoS One, 4, 2009, e5290.
16. 16 Kumar-Singh, R., Farber, D.B., Encapsidated adenovirus mini-chromosome-mediated delivery of genes to the retina: application to the rescue of photoreceptor degeneration. Hum. Mol. Genet. 7 (1998), 1893–1900.
17. 17 Kong, J., Kim, S.R., Binley, K., Pata, I., Doi, K., Mannik, J., Zernant-Rajang, J., Kan, O., Iqball, S., Naylor, S., et al. Correction of the disease phenotype in the mouse model of Stargardt disease by lentiviral gene therapy. Gene Ther. 15 (2008), 1311–1320.
18. 18 Auricchio, A., Kobinger, G., Anand, V., Hildinger, M., O'Connor, E., Maguire, A.M., Wilson, J.M., Bennett, J., Exchange of surface proteins impacts on viral vector cellular specificity and transduction characteristics: the retina as a model. Hum. Mol. Genet. 10 (2001), 3075–3081.
19. 19 Balaggan, K.S., Ali, R.R., Ocular gene delivery using lentiviral vectors. Gene Ther. 19 (2012), 145–153.
20. 20 Cideciyan, A.V., Jacobson, S.G., Beltran, W.A., Sumaroka, A., Swider, M., Iwabe, S., Roman, A.J., Olivares, M.B., Schwartz, S.B., Komáromy, A.M., et al. Human retinal gene therapy for Leber congenital amaurosis shows advancing retinal degeneration despite enduring visual improvement. Proc. Natl. Acad. Sci. USA 110 (2013), E517–E525.
21. 21 Dudus, L., Anand, V., Acland, G.M., Chen, S.-J., Wilson, J.M., Fisher, K.J., Maguire, A.M., Bennett, J., Persistent transgene product in retina, optic nerve and brain after intraocular injection of rAAV. Vision Res. 39 (1999), 2545–2553.
22. 22 Bennett, J., Maguire, A.M., Retina. Ryan, S.J., Schachat, A.P., Wilkinson, C.P., Hinton, D.R., Sadda, S.R., Wiedemann, P., (eds.) Retina, Fifth Edition, 2013, Elsevier, 652–668.
23. 23 Lebherz, C., Maguire, A., Tang, W., Bennett, J., Wilson, J.M., Novel AAV serotypes for improved ocular gene transfer. J. Gene Med. 10 (2008), 375–382.
24. 24 Petrs-Silva, H., Dinculescu, A., Li, Q., Min, S.H., Chiodo, V., Pang, J.J., Zhong, L., Zolotukhin, S., Srivastava, A., Lewin, A.S., Hauswirth, W.W., High-efficiency transduction of the mouse retina by tyrosine-mutant AAV serotype vectors. Mol. Ther. 17 (2009), 463–471.
25. 25 Dalkara, D., Byrne, L.C., Lee, T., Hoffmann, N.V., Schaffer, D.V., Flannery, J.G., Enhanced gene delivery to the neonatal retina through systemic administration of tyrosine-mutated AAV9. Gene Ther. 19 (2012), 176–181.
26. 26 Allocca, M., Mussolino, C., Garcia-Hoyos, M., Sanges, D., Iodice, C., Petrillo, M., Vandenberghe, L.H., Wilson, J.M., Marigo, V., Surace, E.M., Auricchio, A., Novel adeno-associated virus serotypes efficiently transduce murine photoreceptors. J. Virol. 81 (2007), 11372–11380.
27. 27 Dalkara, D., Byrne, L.C., Klimczak, R.R., Visel, M., Yin, L., Merigan, W.H., Flannery, J.G., Schaffer, D.V., In vivo-directed evolution of a new adeno-associated virus for therapeutic outer retinal gene delivery from the vitreous. Sci. Transl. Med., 5, 2013, 189ra76.
28. 28 Cronin, T., Vandenberghe, L.H., Hantz, P., Juttner, J., Reimann, A., Kacsó, A.E., Huckfeldt, R.M., Busskamp, V., Kohler, H., Lagali, P.S., et al. Efficient transduction and optogenetic stimulation of retinal bipolar cells by a synthetic adeno-associated virus capsid and promoter. EMBO Mol. Med. 6 (2014), 1175–1190.
29. 29 Ramachandran, P.S., Lee, V., Wei, Z., Song, J.Y., Casal, G., Cronin, T., Willett, K., Huckfeldt, R., Morgan, J.I., Aleman, T.S., et al. Evaluation of dose and safety of AAV7m8 and AAV8BP2 in the non-human primate retina. Hum. Gene Ther. 28 (2017), 154–167.
30. 30 Zinn, E., Pacouret, S., Khaychuk, V., Turunen, H.T., Carvalho, L.S., Andres-Mateos, E., Shah, S., Shelke, R., Maurer, A.C., Plovie, E., et al. In silico reconstruction of the viral evolutionary lineage yields a potent gene therapy vector. Cell Rep. 12 (2015), 1056–1068.
31. 31 Alexander, J.J., Umino, Y., Everhart, D., Chang, B., Min, S.H., Li, Q., Timmers, A.M., Hawes, N.L., Pang, J.J., Barlow, R.B., Hauswirth, W.W., Restoration of cone vision in a mouse model of achromatopsia. Nat. Med. 13 (2007), 685–687.
32. 32 Macé, E., Caplette, R., Marre, O., Sengupta, A., Chaffiol, A., Barbe, P., Desrosiers, M., Bamberg, E., Sahel, J.A., Picaud, S., et al. Targeting channelrhodopsin-2 to ON-bipolar cells with vitreally administered AAV Restores ON and OFF visual responses in blind mice. Mol. Ther. 23 (2015), 7–16.
33. 33 Mussolino, C., della Corte, M., Rossi, S., Viola, F., Di Vicino, U., Marrocco, E., Neglia, S., Doria, M., Testa, F., Giovannoni, R., et al. AAV-mediated photoreceptor transduction of the pig cone-enriched retina. Gene Ther. 18 (2011), 637–645.
34. 34 Mao, H., James, T. Jr., Schwein, A., Shabashvili, A.E., Hauswirth, W.W., Gorbatyuk, M.S., Lewin, A.S., AAV delivery of wild-type rhodopsin preserves retinal function in a mouse model of autosomal dominant retinitis pigmentosa. Hum. Gene Ther. 22 (2011), 567–575.
35. 35 Khani, S.C., Pawlyk, B.S., Bulgakov, O.V., Kasperek, E., Young, J.E., Adamian, M., Sun, X., Smith, A.J., Ali, R.R., Li, T., AAV-mediated expression targeting of rod and cone photoreceptors with a human rhodopsin kinase promoter. Invest. Ophthalmol. Vis. Sci. 48 (2007), 3954–3961.
36. 36 Miyoshi, H., Takahashi, M., Gage, F.H., Verma, I.M., Stable and efficient gene transfer into the retina using an HIV-based lentiviral vector. Proc. Natl. Acad. Sci. USA 94 (1997), 10319–10323.
37. 37 Nicoud, M., Kong, J., Iqball, S., Kan, O., Naylor, S., Gouras, P., Allikmets, R., Binley, K., Development of photoreceptor-specific promoters and their utility to investigate EIAV lentiviral vector mediated gene transfer to photoreceptors. J. Gene Med. 9 (2007), 1015–1023.
38. 38 Lebherz, C., Auricchio, A., Maguire, A.M., Rivera, V.M., Tang, W., Grant, R.L., Clackson, T., Bennett, J., Wilson, J.M., Long-term inducible gene expression in the eye via adeno-associated virus gene transfer in nonhuman primates. Hum. Gene Ther. 16 (2005), 178–186.
39. 39 Sochor, M.A., Vasireddy, V., Drivas, T.G., Wojno, A., Doung, T., Shpylchak, I., Bennicelli, J., Chung, D., Bennett, J., Lewis, M., An autogenously regulated expression system for gene therapeutic ocular applications. Sci. Rep., 5, 2015, 17105.
40. 40 Aleman, T.S., Han, G., Serrano, L.W., Fuerst, N.M., Charlson, E.S., Pearson, D.J., Chung, D.C., Traband, A., Pan, W., Ying, G.S., et al. Natural history of the central structural abnormalities in choroideremia: a prospective cross-sectional study. Ophthalmology 124 (2017), 359–373.
41. 41 Sengillo, J.D., Justus, S., Cabral, T., Tsang, S.H., Correction of monogenic and common retinal disorders with gene therapy. Genes (Basel), 8, 2017, 53.
42. 42 FDA (2011). Briefing Document: FDA Cellular, Tissue, and Gene Therapies Advisory Committee. CTGTAC Meeting #52; Cellular and Gene Therapies for Retinal Disorders, June 29, 2011 (FDA Cellular, Tissue, and Gene Therapies Advisory Committee).
43. 43 Stingl, K., Bartz-Schmidt, K.U., Besch, D., Chee, C.K., Cottriall, C.L., Gekeler, F., Groppe, M., Jackson, T.L., MacLaren, R.E., Koitschev, A., et al. Subretinal visual implant alpha IMS—clinical trial interim report. Vision Res. 111:Pt B (2015), 149–160.
44. 44 Ghodasra, D.H., Chen, A., Arevalo, J.F., Birch, D.G., Branham, K., Coley, B., Dagnelie, G., de Juan, E., Devenyi, R.G., Dorn, J.D., et al. Worldwide Argus II implantation: recommendations to optimize patient outcomes. BMC Ophthalmol., 16, 2016, 52.
45. 45 Ghodasra, D.H., Chen, A., Arevalo, J.F., Birch, D.G., Branham, K., Coley, B., Dagnelie, G., de Juan, E., Devenyi, R.G., Dorn, J.D., et al. Erratum to: Worldwide Argus II implantation: recommendations to optimize patient outcomes. BMC Ophthalmol., 16, 2016, 129.
46. 46 Geruschat, D.R., Richards, T.P., Arditi, A., da Cruz, L., Dagnelie, G., Dorn, J.D., Duncan, J.L., Ho, A.C., Olmos de Koo, L.C., Sahel, J.A., et al. An analysis of observer-rated functional vision in patients implanted with the Argus II retinal prosthesis system at three years. Clin. Exp. Optom. 99 (2016), 227–232.
47. 47 Ashtari, M., Cyckowski, L., Yazdi, A., Viands, A., Marshall, K., Bókkon, I., Maguire, A., Bennett, J., fMRI of retina-originated phosphenes experienced by patients with Leber congenital amaurosis. PLoS One, 9, 2014, e86068.
48. 48 MacLaren, R.E., Bennett, J., Schwartz, S.D., Gene therapy and stem cell transplantation in retinal disease: the new frontier. Ophthalmology 123:10S (2016), S98–S106.
49. 49 Dejneka, N.S., Surace, E.M., Aleman, T.S., Cideciyan, A.V., Lyubarsky, A., Savchenko, A., Redmond, T.M., Tang, W., Wei, Z., Rex, T.S., et al. In utero gene therapy rescues vision in a murine model of congenital blindness. Mol. Ther. 9 (2004), 182–188.
50. 50 Mather, G., Visual physiology. Mather, G., (eds.) Foundations of Sensation and Perception, Second Edition, 2008, Psychology Press, 196–235.
51. 51 Ashtari, M., Cyckowski, L.L., Monroe, J.F., Marshall, K.A., Chung, D.C., Auricchio, A., Simonelli, F., Leroy, B.P., Maguire, A.M., Shindler, K.S., Bennett, J., The human visual cortex responds to gene therapy-mediated recovery of retinal function. J. Clin. Invest. 121 (2011), 2160–2168.
52. 52 Ashtari, M., Zhang, H., Cook, P.A., Cyckowski, L.L., Shindler, K.S., Marshall, K.A., Aravand, P., Vossough, A., Gee, J.C., Maguire, A.M., et al. Plasticity of the human visual system after retinal gene therapy in patients with Leber's congenital amaurosis. Sci. Transl. Med., 7, 2015, 296ra110.
53. 53 Chévez-Barrios, P., Chintagumpala, M., Mieler, W., Paysse, E., Boniuk, M., Kozinetz, C., Hurwitz, M.Y., Hurwitz, R.L., Response of retinoblastoma with vitreous tumor seeding to adenovirus-mediated delivery of thymidine kinase followed by ganciclovir. J. Clin. Oncol. 23 (2005), 7927–7935.
54. 54 Campochiaro, P.A., Nguyen, Q.D., Shah, S.M., Klein, M.L., Holz, E., Frank, R.N., Saperstein, D.A., Gupta, A., Stout, J.T., Macko, J., et al. Adenoviral vector-delivered pigment epithelium-derived factor for neovascular age-related macular degeneration: results of a phase I clinical trial. Hum. Gene Ther. 17 (2006), 167–176.
55. 55 Maguire, A.M., Simonelli, F., Pierce, E.A., Pugh, E.N. Jr., Mingozzi, F., Bennicelli, J., Banfi, S., Marshall, K.A., Testa, F., Surace, E.M., et al. Safety and efficacy of gene transfer for Leber's congenital amaurosis. N. Engl. J. Med. 358 (2008), 2240–2248.
56. 56 Hauswirth, W.W., Aleman, T.S., Kaushal, S., Cideciyan, A.V., Schwartz, S.B., Wang, L., Conlon, T.J., Boye, S.L., Flotte, T.R., Byrne, B.J., Jacobson, S.G., Treatment of Leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial. Hum. Gene Ther. 19 (2008), 979–990.
57. 57 Bainbridge, J.W., Smith, A.J., Barker, S.S., Robbie, S., Henderson, R., Balaggan, K., Viswanathan, A., Holder, G.E., Stockman, A., Tyler, N., et al. Effect of gene therapy on visual function in Leber's congenital amaurosis. N. Engl. J. Med. 358 (2008), 2231–2239.
58. 58 Bennett, J., Wellman, J., Marshall, K.A., McCague, S., Ashtari, M., DiStefano-Pappas, J., Elci, O.U., Chung, D.C., Sun, J., Wright, J.F., et al. Safety and durability of effect of contralateral-eye administration of AAV2 gene therapy in patients with childhood-onset blindness caused by RPE65 mutations: a follow-on phase 1 trial. Lancet 388 (2016), 661–672.
59. 59 Constable, I.J., Blumenkranz, M.S., Schwartz, S.D., Barone, S., Lai, C.M., Rakoczy, E.P., Gene therapy for age-related macular degeneration. Asia Pac. J. Ophthalmol. (Phila.) 5 (2016), 300–303.
60. 60 Feuer, W.J., Schiffman, J.C., Davis, J.L., Porciatti, V., Gonzalez, P., Koilkonda, R.D., Yuan, H., Lalwani, A., Lam, B.L., Guy, J., Gene therapy for leber hereditary optic neuropathy: initial results. Ophthalmology 123 (2016), 558–570.
61. 61 Redmond, T.M., Poliakov, E., Yu, S., Tsai, J.Y., Lu, Z., Gentleman, S., Mutation of key residues of RPE65 abolishes its enzymatic role as isomerohydrolase in the visual cycle. Proc. Natl. Acad. Sci. USA 102 (2005), 13658–13663.
62. 62 Acland, G.M., Aguirre, G.D., Ray, J., Zhang, Q., Aleman, T.S., Cideciyan, A.V., Pearce-Kelling, S.E., Anand, V., Zeng, Y., Maguire, A.M., et al. Gene therapy restores vision in a canine model of childhood blindness. Nat. Genet. 28 (2001), 92–95.
63. 63 Acland, G.M., Aguirre, G.D., Bennett, J., Aleman, T.S., Cideciyan, A.V., Bennicelli, J., Dejneka, N.S., Pearce-Kelling, S.E., Maguire, A.M., Palczewski, K., et al. Long-term restoration of rod and cone vision by single dose rAAV-mediated gene transfer to the retina in a canine model of childhood blindness. Mol. Ther. 12 (2005), 1072–1082.
64. 64 Bennicelli, J., Wright, J.F., Komaromy, A., Jacobs, J.B., Hauck, B., Zelenaia, O., Mingozzi, F., Hui, D., Chung, D., Rex, T.S., et al. Reversal of blindness in animal models of Leber congenital amaurosis using optimized AAV2-mediated gene transfer. Mol. Ther. 16 (2008), 458–465.
65. 65 Weleber, R.G., Pennesi, M.E., Wilson, D.J., Kaushal, S., Erker, L.R., Jensen, L., McBride, M.T., Flotte, T.R., Humphries, M., Calcedo, R., et al. Results at 2 years after gene therapy for RPE65-deficient Leber congenital amaurosis and severe early-childhood-onset retinal dystrophy. Ophthalmology 123 (2016), 1606–1620.
66. 66 Jacobson, S.G., Cideciyan, A.V., Roman, A.J., Sumaroka, A., Schwartz, S.B., Heon, E., Hauswirth, W.W., Improvement and decline in vision with gene therapy in childhood blindness. N. Engl. J. Med. 372 (2015), 1920–1926.
67. 67 Bainbridge, J.W., Mehat, M.S., Sundaram, V., Robbie, S.J., Barker, S.E., Ripamonti, C., Georgiadis, A., Mowat, F.M., Beattie, S.G., Gardner, P.J., et al. Long-term effect of gene therapy on Leber's congenital amaurosis. N. Engl. J. Med. 372 (2015), 1887–1897.
68. 68 Bennett, J., Ashtari, M., Wellman, J., Marshall, K.A., Cyckowski, L.L., Chung, D.C., McCague, S., Pierce, E.A., Chen, Y., Bennicelli, J.L., et al. AAV2 gene therapy readministration in three adults with congenital blindness. Sci. Transl. Med., 4, 2012, 120ra15.
69. 69 Edwards, T.L., Jolly, J.K., Groppe, M., Barnard, A.R., Cottriall, C.L., Tolmachova, T., Black, G.C., Webster, A.R., Lotery, A.J., Holder, G.E., et al. Visual acuity after retinal gene therapy for choroideremia. N. Engl. J. Med. 374 (2016), 1996–1998.
70. 70 MacLaren, R.E., Groppe, M., Barnard, A.R., Cottriall, C.L., Tolmachova, T., Seymour, L., Clark, K.R., During, M.J., Cremers, F.P., Black, G.C., et al. Retinal gene therapy in patients with choroideremia: initial findings from a phase 1/2 clinical trial. Lancet 383 (2014), 1129–1137.
71. 71 Ghazi, N.G., Abboud, E.B., Nowilaty, S.R., Alkuraya, H., Alhommadi, A., Cai, H., Hou, R., Deng, W.T., Boye, S.L., Almaghamsi, A., et al. Treatment of retinitis pigmentosa due to MERTK mutations by ocular subretinal injection of adeno-associated virus gene vector: results of a phase I trial. Hum. Genet. 135 (2016), 327–343.
72. 72 Constable, I.J., Pierce, C.M., Lai, C.M., Magno, A.L., Degli-Esposti, M.A., French, M.A., McAllister, I.L., Butler, S., Barone, S.B., Schwartz, S.D., et al. Phase 2a randomized clinical trial: safety and post hoc analysis of subretinal rAAV.sFLT-1 for wet age-related macular degeneration. EBioMedicine 14 (2016), 168–175.
73. 73 Rakoczy, E.P., Lai, C.M., Magno, A.L., Wikstrom, M.E., French, M.A., Pierce, C.M., Schwartz, S.D., Blumenkranz, M.S., Chalberg, T.W., Degli-Esposti, M.A., Constable, I.J., Gene therapy with recombinant adeno-associated vectors for neovascular age-related macular degeneration: 1 year follow-up of a phase 1 randomised clinical trial. Lancet 386 (2015), 2395–2403.
74. 74 Bakondi, B., Lv, W., Lu, B., Jones, M.K., Tsai, Y., Kim, K.J., Levy, R., Akhtar, A.A., Breunig, J.J., Svendsen, C.N., Wang, S., In vivo CRISPR/Cas9 gene editing corrects retinal dystrophy in the S334ter-3 rat model of autosomal dominant retinitis pigmentosa. Mol. Ther. 24 (2016), 556–563.
75. 75 Trapani, I., Toriello, E., de Simone, S., Colella, P., Iodice, C., Polishchuk, E.V., Sommella, A., Colecchi, L., Rossi, S., Simonelli, F., et al. Improved dual AAV vectors with reduced expression of truncated proteins are safe and effective in the retina of a mouse model of Stargardt disease. Hum. Mol. Genet. 24 (2015), 6811–6825.
76. 76 Vasireddy, V., Mills, J.A., Gaddameedi, R., Basner-Tschakarjan, E., Kohnke, M., Black, A.D., Alexandrov, K., Zhou, S., Maguire, A.M., Chung, D.C., et al. AAV-mediated gene therapy for choroideremia: preclinical studies in personalized models. PLoS One, 8, 2013, e61396.
77. 77 Maguire, A.M., High, K.A., Auricchio, A., Wright, J.F., Pierce, E.A., Testa, F., Mingozzi, F., Bennicelli, J.L., Ying, G.S., Rossi, S., et al. Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial. Lancet 374 (2009), 1597–1605.
78. 78 Bennett, J., Maguire, A.M., Wright, J.F., Marshall, K.A., Bennicelli, J., Leroy, B.P., Auricchio, A., Simonelli, F., McDonnell, J.W., High, K.A., Gene therapy-mediated reversal of congenital blindness: demonstration of efficacy in a phase 1 safety trial. Mol. Ther, 17, 2009, S167.
79. 79 Simonelli, F., Maguire, A.M., Testa, F., Pierce, E.A., Mingozzi, F., Bennicelli, J.L., Rossi, S., Marshall, K., Banfi, S., Surace, E.M., et al. Gene therapy for Leber's congenital amaurosis is safe and effective through 1.5 years after vector administration. Mol. Ther. 18 (2010), 643–650.
80. 80 Testa, F., Maguire, A.M., Rossi, S., Pierce, E.A., Melillo, P., Marshall, K., Banfi, S., Surace, E.M., Sun, J., Acerra, C., et al. Three-year follow-up after unilateral subretinal delivery of adeno-associated virus in patients with Leber congenital amaurosis type 2. Ophthalmology 120 (2013), 1283–1291.
81. 81 Jacobson, S.G., Cideciyan, A.V., Ratnakaram, R., Heon, E., Schwartz, S.B., Roman, A.J., Peden, M.C., Aleman, T.S., Boye, S.L., Sumaroka, A., et al. Gene therapy for Leber congenital amaurosis caused by RPE65 mutations: safety and efficacy in 15 children and adults followed up to 3 years. Arch. Ophthalmol. 130 (2012), 9–24.
82. 82 Cideciyan, A.V., Hauswirth, W.W., Aleman, T.S., Kaushal, S., Schwartz, S.B., Boye, S.L., Windsor, E.A., Conlon, T.J., Sumaroka, A., Roman, A.J., et al. Vision 1 year after gene therapy for Leber's congenital amaurosis. N. Engl. J. Med. 361 (2009), 725–727.
83. 83 Cideciyan, A.V., Hauswirth, W.W., Aleman, T.S., Kaushal, S., Schwartz, S.B., Boye, S.L., Windsor, E.A., Conlon, T.J., Sumaroka, A., Pang, J.J., et al. Human RPE65 gene therapy for Leber congenital amaurosis: persistence of early visual improvements and safety at 1 year. Hum. Gene Ther. 20 (2009), 999–1004.
84. 84 Cideciyan, A.V., Aleman, T.S., Boye, S.L., Schwartz, S.B., Kaushal, S., Roman, A.J., Pang, J.J., Sumaroka, A., Windsor, E.A., Wilson, J.M., et al. Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kinetics. Proc. Natl. Acad. Sci. USA 105 (2008), 15112–15117.
85. 85 Banin, E., Bandah-Rozenfeld, D., Obolensky, A., Cideciyan, A.V., Aleman, T.S., Marks-Ohana, D., Sela, M., Boye, S., Sumaroka, A., Roman, A.J., et al. Molecular anthropology meets genetic medicine to treat blindness in the North African Jewish population: human gene therapy initiated in Israel. Hum. Gene Ther. 21 (2010), 1749–1757.
86. 86 Wan, X., Pei, H., Zhao, M.J., Yang, S., Hu, W.K., He, H., Ma, S.Q., Zhang, G., Dong, X.Y., Chen, C., et al. Efficacy and safety of rAAV2-ND4 treatment for Leber's hereditary optic neuropathy. Sci. Rep., 6, 2016, 21587.
87. 87 Campochiaro, P.A., Lauer, A.K., Sohn, E.H., Mir, T.A., Naylor, S., Anderton, M.C., Kelleher, M., Harrop, R., Ellis, S., Mitrophanous, K.A., Lentiviral vector gene transfer of endostatin/angiostatin for macular degeneration (GEM) study. Hum. Gene Ther. 28 (2017), 99–111.
88. 88 Nathans, J., Thomas, D., Hogness, D.S., Molecular genetics of human color vision: the genes encoding blue, green, and red pigments. Science 232 (1986), 193–202.
89. 89 Zhang, J., Schweers, B., Dyer, M.A., The first knockout mouse model of retinoblastoma. Cell Cycle 3 (2004), 952–959.
90. 90 Goddard, A.D., Balakier, H., Canton, M., Dunn, J., Squire, J., Reyes, E., Becker, A., Phillips, R.A., Gallie, B.L., Infrequent genomic rearrangement and normal expression of the putative RB1 gene in retinoblastoma tumors. Mol. Cell. Biol. 8 (1988), 2082–2088.
91. 91 Friend, S.H., Horowitz, J.M., Gerber, M.R., Wang, X.F., Bogenmann, E., Li, F.P., Weinberg, R.A., Deletions of a DNA sequence in retinoblastomas and mesenchymal tumors: organization of the sequence and its encoded protein. Proc. Natl. Acad. Sci. USA 84 (1987), 9059–9063.
92. 92 Lin, C.S., Sharpley, M.S., Fan, W., Waymire, K.G., Sadun, A.A., Carelli, V., Ross-Cisneros, F.N., Baciu, P., Sung, E., McManus, M.J., et al. Mouse mtDNA mutant model of Leber hereditary optic neuropathy. Proc. Natl. Acad. Sci. USA 109 (2012), 20065–20070.
93. 93 Qi, X., Sun, L., Lewin, A.S., Hauswirth, W.W., Guy, J., The mutant human ND4 subunit of complex I induces optic neuropathy in the mouse. Invest. Ophthalmol. Vis. Sci. 48 (2007), 1–10.
94. 94 Wallace, D.C., Singh, G., Lott, M.T., Hodge, J.A., Schurr, T.G., Lezza, A.M., Elsas, L.J. 2nd, Nikoskelainen, E.K., Mitochondrial DNA mutation associated with Leber's hereditary optic neuropathy. Science 242 (1988), 1427–1430.
95. 95 Seabra, M.C., Tolmachova, T., Anders, R., Abrink, M., Ramalho, J.S., Futter, C., Tonagel, F., Tanimoto, N., Seeliger, M., Huxley, C., Choroideremia mouse model generated by conditional Rep1 knock-out. Invest. Ophthalmol. Vis. Sci., 46, 2005, 3556.
96. 96 Cremers, F.P.M., van de Pol, D.J.R., van Kerkhoff, L.P.M., Wieringa, B., Ropers, H.-H., Cloning of a gene that is rearranged in patients with choroideraemia. Nature 347 (1990), 674–677.
97. 97 Cremers, F.P., Brunsmann, F., Berger, W., van Kerkhoff, E.P., van de Pol, T.J., Wieringa, B., Pawlowitzki, I.H., Ropers, H.H., Cloning of the breakpoints of a deletion associated with choroidermia. Hum. Genet. 86 (1990), 61–64.
98. 98 Olsson, J.E., Gordon, J.W., Pawlyk, B.S., Roof, D., Hayes, A., Molday, R.S., Mukai, S., Cowley, G.S., Berson, E.L., Dryja, T.P., Transgenic mice with a rhodopsin mutation (Pro23His): a mouse model of autosomal dominant retinitis pigmentosa. Neuron 9 (1992), 815–830.
99. 99 Humphries, M.M., Rancourt, D., Farrar, G.J., Kenna, P., Hazel, M., Bush, R.A., Sieving, P.A., Sheils, D.M., McNally, N., Creighton, P., et al. Retinopathy induced in mice by targeted disruption of the rhodopsin gene. Nat. Genet. 15 (1997), 216–219.
100. 100 Dryja, T.P., McGee, T.L., Reichel, E., Hahn, L.B., Cowley, G.S., Yandell, D.W., Sandberg, M.A., Berson, E.L., A point mutation of the rhodopsin gene in one form of retinitis pigmentosa. Nature 343 (1990), 364–366.
101. 101 Dryja, T.P., McGee, T.L., Hahn, L.B., Cowley, G.S., Olsson, J.E., Reichel, E., Sandberg, M.A., Berson, E.L., Mutations within the rhodopsin gene in patients with autosomal dominant retinitis pigmentosa. N. Engl. J. Med. 323 (1990), 1302–1307.
102. 102 Farrar, G.J., Kenna, P., Redmond, R., Shiels, D., McWilliam, P., Humphries, M.M., Sharp, E.M., Jordan, S., Kumar-Singh, R., Humphries, P., Autosomal dominant retinitis pigmentosa: a mutation in codon 178 of the rhodopsin gene in two families of Celtic origin. Genomics 11 (1991), 1170–1171.
103. 103 Berger, W., van de Pol, D., Bächner, D., Oerlemans, F., Winkens, H., Hameister, H., Wieringa, B., Hendriks, W., Ropers, H.H., An animal model for Norrie disease (ND): gene targeting of the mouse ND gene. Hum. Mol. Genet. 5 (1996), 51–59.
104. 104 Berger, W., van de Pol, D., Warburg, M., Gal, A., Bleeker-Wagemakers, L., de Silva, H., Meindl, A., Meitinger, T., Cremers, F., Ropers, H.H., Mutations in the candidate gene for Norrie disease. Hum. Mol. Genet. 1 (1992), 461–465.
105. 105 Hiebler, S., Masuda, T., Hacia, J.G., Moser, A.B., Faust, P.L., Liu, A., Chowdhury, N., Huang, N., Lauer, A., Bennett, J., et al. The Pex1-G844D mouse: a model for mild human Zellweger spectrum disorder. Mol. Genet. Metab. 111 (2014), 522–532.
106. 106 Shimozawa, N., Tsukamoto, T., Suzuki, Y., Orii, T., Shirayoshi, Y., Mori, T., Fujiki, Y., A human gene responsible for Zellweger syndrome that affects peroxisome assembly. Science 255 (1992), 1132–1134.
107. 107 Clarke, G., Goldberg, A.F., Vidgen, D., Collins, L., Ploder, L., Schwarz, L., Molday, L.L., Rossant, J., Szél, A., Molday, R.S., et al. Rom-1 is required for rod photoreceptor viability and the regulation of disk morphogenesis. Nat. Genet. 25 (2000), 67–73.
108. 108 Bascom, R.A., Manara, S., Collins, L., Molday, R.S., Kalnins, V.I., McInnes, R.R., Cloning of the cDNA for a novel photoreceptor membrane protein (rom-1) identifies a disk rim protein family implicated in human retinopathies. Neuron 8 (1992), 1171–1184.
109. 109 Brown, M.D., Voljavec, A.S., Lott, M.T., Torroni, A., Yang, C.C., Wallace, D.C., Mitochondrial DNA complex I and III mutations associated with Leber's hereditary optic neuropathy. Genetics 130 (1992), 163–173.
110. 110 Connell, G., Bascom, R., Molday, L., Reid, D., McInnes, R.R., Molday, R.S., Photoreceptor peripherin is the normal product of the gene responsible for retinal degeneration in the rds mouse. Proc. Natl. Acad. Sci. USA 88 (1991), 723–726.
111. 111 Kajiwara, K., Sandberg, M.A., Berson, E.L., Dryja, T.P., A null mutation in the human peripherin/RDS gene in a family with autosomal dominant retinitis punctata albescens. Nat. Genet. 3 (1993), 208–212.
112. 112 Kemp, C.M., Jacobson, S.G., Cideciyan, A.V., Kimura, A.E., Sheffield, V.C., Stone, E.M., RDS gene mutations causing retinitis pigmentosa or macular degeneration lead to the same abnormality in photoreceptor function. Invest. Ophthalmol. Vis. Sci. 35 (1994), 3154–3162.
113. 113 Nakazawa, M., Kikawa, E., Chida, Y., Wada, Y., Shiono, T., Tamai, M., Autosomal dominant cone-rod dystrophy associated with mutations in codon 244 (Asn244His) and codon 184 (Tyr184Ser) of the peripherin/RDS gene. Arch. Ophthalmol. 114 (1996), 72–78.
114. 114 McLaughlin, M.E., Sandberg, M.A., Berson, E.L., Dryja, T.P., Recessive mutations in the gene encoding the beta-subunit of rod phosphodiesterase in patients with retinitis pigmentosa. Nat. Genet. 4 (1993), 130–134.
115. 115 Gupta, A.R., Maguire, A.M., Milam, A.H., Cideciyan, A.V., Kingsley, R.M., Stone, E.M., Jacobson, S.J., Bennett, J., Retinopathy in mice transgenic for a mutant human TIMP3 gene that causes Sorsby Fundus Dystrophy. Invest. Ophthalmol. Vis. Sci., 40, 1999, S919.
116. 116 Weber, B.H., Vogt, G., Pruett, R.C., Stöhr, H., Felbor, U., Mutations in the tissue inhibitor of metalloproteinases-3 (TIMP3) in patients with Sorsby's fundus dystrophy. Nat. Genet. 8 (1994), 352–356.
117. 117 Conley, S.M., Stuck, M.W., Watson, J.N., Naash, M.I., Rom1 converts Y141C-Prph2-associated pattern dystrophy to retinitis pigmentosa. Hum. Mol. Genet. 26 (2017), 509–518.
118. 118 Kajiwara, K., Berson, E.L., Dryja, T.P., Digenic retinitis pigmentosa due to mutations at the unlinked peripherin/RDS and ROM1 loci. Science 264 (1994), 1604–1608.
119. 119 Sakamoto, K., McCluskey, M., Wensel, T.G., Naggert, J.K., Nishina, P.M., New mouse models for recessive retinitis pigmentosa caused by mutations in the Pde6a gene. Hum. Mol. Genet. 18 (2009), 178–192.
120. 120 Huang, S.H., Pittler, S.J., Huang, X., Oliveira, L., Berson, E.L., Dryja, T.P., Autosomal recessive retinitis pigmentosa caused by mutations in the alpha subunit of rod cGMP phosphodiesterase. Nat. Genet. 11 (1995), 468–471.
121. 121 Chen, J., Simon, M.I., Matthes, M.T., Yasumura, D., LaVail, M.M., Increased susceptibility to light damage in an arrestin knockout mouse model of Oguchi disease (stationary night blindness). Invest. Ophthalmol. Vis. Sci. 40 (1999), 2978–2982.
122. 122 Fuchs, S., Nakazawa, M., Maw, M., Tamai, M., Oguchi, Y., Gal, A., A homozygous 1-base pair deletion in the arrestin gene is a frequent cause of Oguchi disease in Japanese. Nat. Genet. 10 (1995), 360–362.
123. 123 Lamminen, T., Majander, A., Juvonen, V., Wikström, M., Aula, P., Nikoskelainen, E., Savontous, M.L., A mitochondrial mutation at nt 9101 in the ATP synthase 6 gene associated with deficient oxidative phosphorylation in a family with Leber hereditary optic neuroretinopathy. Am. J. Hum. Genet. 56 (1995), 1238–1240.
124. 124 Liu, X., Ondek, B., Williams, D.S., Mutant myosin VIIa causes defective melanosome distribution in the RPE of shaker-1 mice. Nat. Genet. 19 (1998), 117–118.
125. 125 Weil, D., Blanchard, S., Kaplan, J., Guilford, P., Gibson, F., Walsh, J., Mburu, P., Varela, A., Levilliers, J., Weston, M.D., et al. Defective myosin VIIA gene responsible for Usher syndrome type 1B. Nature 374 (1995), 60–61.
126. 126 Zhang, Q., Acland, G.M., Wu, W.X., Johnson, J.L., Pearce-Kelling, S., Tulloch, B., Vervoort, R., Wright, A.F., Aguirre, G.D., Different RPGR exon ORF15 mutations in Canids provide insights into photoreceptor cell degeneration. Hum. Mol. Genet. 11 (2002), 993–1003.
127. 127 Meindl, A., Dry, K., Herrmann, K., Manson, F., Ciccodicola, A., Edgar, A., Carvalho, M.R., Achatz, H., Hellebrand, H., Lennon, A., et al. A gene (RPGR) with homology to the RCC1 guanine nucleotide exchange factor is mutated in X-linked retinitis pigmentosa (RP3). Nat. Genet. 13 (1996), 35–42.
128. 128 Semple-Rowland, S.L., Lee, N.R., Van Hooser, J.P., Palczewski, K., Baehr, W., A null mutation in the photoreceptor guanylate cyclase gene causes the retinal degeneration chicken phenotype. Proc. Natl. Acad. Sci. USA 95 (1998), 1271–1276.
129. 129 Perrault, I., Rozet, J.M., Calvas, P., Gerber, S., Camuzat, A., Dollfus, H., Châtelin, S., Souied, E., Ghazi, I., Leowski, C., et al. Retinal-specific guanylate cyclase gene mutations in Leber's congenital amaurosis. Nat. Genet. 14 (1996), 461–464.
130. 130 Richards, A.J., Yates, J.R., Williams, R., Payne, S.J., Pope, F.M., Scott, J.D., Snead, M.P., A family with Stickler syndrome type 2 has a mutation in the COL11A1 gene resulting in the substitution of glycine 97 by valine in alpha 1 (XI) collagen. Hum. Mol. Genet. 5 (1996), 1339–1343.
131. 131 Mitchison, H.M., Bernard, D.J., Greene, N.D., Cooper, J.D., Junaid, M.A., Pullarkat, R.K., de Vos, N., Breuning, M.H., Owens, J.W., Mobley, W.C., et al. Targeted disruption of the Cln3 gene provides a mouse model for Batten disease. The Batten Mouse Model Consortium [corrected]. Neurobiol. Dis. 6 (1999), 321–334.
132. 132 Greene, N.D., Bernard, D.L., Taschner, P.E., Lake, B.D., de Vos, N., Breuning, M.H., Gardiner, R.M., Mole, S.E., Nussbaum, R.L., Mitchison, H.M., A murine model for juvenile NCL: gene targeting of mouse Cln3. Mol. Genet. Metab. 66 (1999), 309–313.
133. 133 The International Batten Disease Consortium. Isolation of a novel gene underlying Batten disease, CLN3. Cell 82 (1995), 949–957.
134. 134 Favor, J., Sandulache, R., Neuhäuser-Klaus, A., Pretsch, W., Chatterjee, B., Senft, E., Wurst, W., Blanquet, V., Grimes, P., Spörle, R., Schughart, K., The mouse Pax2(1Neu) mutation is identical to a human PAX2 mutation in a family with renal-coloboma syndrome and results in developmental defects of the brain, ear, eye, and kidney. Proc. Natl. Acad. Sci. USA 93 (1996), 13870–13875.
135. 135 Léveillard, T., Mohand-Saïd, S., Lorentz, O., Hicks, D., Fintz, A.C., Clérin, E., Simonutti, M., Forster, V., Cavusoglu, N., Chalmel, F., et al. Identification and characterization of rod-derived cone viability factor. Nat. Genet. 36 (2004), 755–759.
136. 136 Rex, T.S., Kasmala, L., Bond, W.S., de Lucas Cerrillo, A.M., Wynn, K., Lewin, A.S., Erythropoietin slows photoreceptor cell death in a mouse model of autosomal dominant retinitis pigmentosa. PLoS One, 11, 2016, e0157411.